+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vasomotor Symptoms - Global Strategic Business Report

  • PDF Icon

    Report

  • 376 Pages
  • November 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6110926
The global market for Vasomotor Symptoms was valued at US$3.9 Billion in 2025 and is projected to reach US$6.1 Billion by 2032, growing at a CAGR of 6.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Vasomotor Symptoms Market - Key Trends & Drivers Summarized

Why Are Vasomotor Symptoms Garnering Greater Clinical and Pharmaceutical Attention Today?

Vasomotor symptoms (VMS), primarily characterized by hot flashes and night sweats, are among the most prevalent and disruptive manifestations of menopause. Affecting up to 80% of perimenopausal and postmenopausal women globally, these symptoms have traditionally been underdiagnosed and under-addressed in clinical settings. However, recent years have witnessed a growing medical consensus on the need to treat VMS not merely as a discomfort but as a condition with significant impacts on sleep, cardiovascular function, and quality of life. This paradigm shift is driving increased demand for therapeutic options across multiple drug classes and delivery formats.

While hormone replacement therapy (HRT) remains the gold standard in many cases, its use is often limited due to risks associated with breast cancer, thromboembolism, and cardiovascular disease in some patient groups. As a result, there is rising demand for non-hormonal interventions including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and more recently, neurokinin-3 (NK3) receptor antagonists. This therapeutic expansion is accompanied by heightened screening, awareness campaigns, and regulatory approvals that together are broadening the VMS treatment landscape, particularly in North America and Europe.

How Is Innovation in Drug Development and Delivery Enhancing VMS Management?

The pharmaceutical innovation pipeline for vasomotor symptoms is being reshaped by a surge in interest in non-hormonal and targeted therapies. The approval of fezolinetant, an oral NK3 receptor antagonist, marks a significant milestone as it directly targets thermoregulatory dysfunction believed to cause VMS. Its market entry has catalyzed development in similar classes by other pharmaceutical players, with multiple NK3 antagonists currently in Phase II and III trials. These innovations are pivotal for patients contraindicated for hormone therapy and may define a new standard of care in VMS treatment.

Drug delivery formats are also evolving to improve adherence and patient preference. Transdermal patches, vaginal rings, and topical sprays are gaining market share alongside traditional oral pills, addressing both systemic and localized symptoms. Complementary to prescription-based solutions, the over-the-counter (OTC) and nutraceutical segments are seeing robust activity, particularly in botanicals such as black cohosh, red clover, and soy isoflavones, though clinical efficacy remains mixed. Additionally, digital therapeutics including CBT-based apps targeting sleep and mood disturbances from VMS are emerging as adjunct tools, especially in markets with high digital literacy.

Where Is Market Adoption Accelerating and What Patient Segments Are Driving Growth?

The most mature markets for vasomotor symptom therapies are in the U.S., Canada, and several European nations where menopause awareness and healthcare access are relatively high. In the U.S., direct-to-consumer (DTC) platforms and femtech companies are aggressively pushing personalized menopause care, including VMS-specific solutions bundled with virtual consultations, remote prescriptions, and lab testing. The commercial success of brands targeting menopausal women with discrete and dignified support services is reinforcing demand in adjacent categories such as sleep aids, mental health, and sexual wellness.

In Asia-Pacific and Latin America, the VMS market is gaining traction as demographic transitions increase the menopausal population, and stigma around menopause begins to erode. Urban centers in Japan, South Korea, and China are emerging as high-growth hubs where Western therapies are being adapted to local preferences. Additionally, a younger demographic of health-conscious perimenopausal women aged 40-50 is emerging as a key consumer group, particularly in private healthcare systems. These women are seeking early interventions, lifestyle-aligned treatment options, and holistic approaches to managing hormonal changes.

What Forces Are Powering the Expansion of the Global VMS Market?

The growth in the vasomotor symptoms market is driven by several factors, including increasing female life expectancy, greater openness to menopause-related healthcare, and a rapidly expanding product pipeline. As women spend a third of their lives in postmenopause, the demand for long-term, safe, and effective treatments is growing. Enhanced awareness campaigns, employer-sponsored wellness programs, and the destigmatization of menopause across social platforms are all encouraging treatment-seeking behavior. Health insurers and providers are also beginning to integrate menopause care into broader women’s health services.

Pharmaceutical innovation-especially in non-hormonal drug classes-remains a critical growth driver. The entry of blockbuster therapies such as fezolinetant has catalyzed investment from mid- and large-cap pharmaceutical companies. Regulatory bodies are increasingly receptive to fast-track approvals given the previously unmet needs in this segment. The rise of femtech and digital therapeutics is adding further momentum, offering scalable and personalized solutions that make VMS care more accessible. Collectively, these shifts point toward a significant expansion of the VMS market globally, with both prescription and consumer wellness pathways contributing to its long-term trajectory.

Report Scope

The report analyzes the Vasomotor Symptoms market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Therapy Type (Estrogen Therapy, Progesterone Therapy, Combination Therapy, OTC Hormone Therapy, Anti-Depressants Therapy, Other Therapy Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores); End-User (Hospitals & Clinics End-User, Specialty Centers End-User, Other End-Users)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Estrogen Therapy segment, which is expected to reach US$1.7 Billion by 2032 with a CAGR of a 8.4%. The Progesterone Therapy segment is also set to grow at 4.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $1.1 Billion in 2025, and China, forecasted to grow at an impressive 10.4% CAGR to reach $1.3 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Vasomotor Symptoms Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Vasomotor Symptoms Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Vasomotor Symptoms Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Astellas Pharma, Bayer AG, Biogen (partnering), Bionovo, Boehringer Ingelheim and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Vasomotor Symptoms market report include:

  • Astellas Pharma
  • Bayer AG
  • Biogen (partnering)
  • Bionovo
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gedeon Richter
  • GlaxoSmithKline (GSK)
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co.
  • NeRRe Therapeutics
  • NeRRe Therapeutics (dual)
  • Noema Pharma
  • Noven Pharmaceuticals
  • Novo Nordisk
  • Ogeda (now Astellas)
  • Pfizer (Duavee)
  • Pfizer Inc.
  • Shionogi & Co.

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind
  • Vasomotor Symptoms - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Awareness of Menopausal Health Throws the Spotlight on Vasomotor Symptom Management Solutions
  • Increasing Female Geriatric Population Spurs Demand for Effective Therapies to Treat Hot Flashes and Night Sweats
  • Shift Toward Non-Hormonal Treatment Options Expands Addressable Market for Alternative and Natural Remedies
  • Increased Focus on Women's Health Equity Strengthens the Business Case for Targeted VMS Therapeutics
  • Innovation in Neurokinin Receptor Antagonists Drives Growth in Prescription-Based Non-Hormonal VMS Treatments
  • Growth in Digital Health and Telemedicine Enhances Access to VMS Consultations and Remote Prescription Services
  • Consumer Shift Toward Personalized Health Fuels Demand for Tailored Hormone Therapy and Functional Medicine
  • Management Products
  • Research Linking VMS with Long-Term Cardiovascular and Metabolic Risk Increases Screening and Intervention Rates
  • Innovation in Wearable Cooling Devices and Smart Clothing Adds Momentum to Non-Pharmacologic Solutions
  • Retail Health Clinics and Pharmacies Drive Accessibility of Menopause and VMS-Related Treatment Avenues
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Vasomotor Symptoms Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Vasomotor Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Vasomotor Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Vasomotor Symptoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Estrogen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Estrogen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Progesterone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Progesterone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Progesterone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for OTC Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for OTC Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for OTC Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Anti-Depressants Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Anti-Depressants Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Anti-Depressants Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Hospitals & Clinics End-User by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Hospitals & Clinics End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Specialty Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Specialty Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Specialty Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 31: World 13-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 33: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 34: World 13-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 35: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 36: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 37: World 13-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 38: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 39: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 40: World 13-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAIN
RUSSIA
REST OF EUROPE
AUSTRALIA
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
  • Vasomotor Symptoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Astellas Pharma
  • Bayer AG
  • Biogen (partnering)
  • Bionovo
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Gedeon Richter
  • GlaxoSmithKline (GSK)
  • HRA Pharma
  • Johnson & Johnson
  • Merck & Co.
  • NeRRe Therapeutics
  • NeRRe Therapeutics (dual)
  • Noema Pharma
  • Noven Pharmaceuticals
  • Novo Nordisk
  • Ogeda (now Astellas)
  • Pfizer (Duavee)
  • Pfizer Inc.
  • Shionogi & Co.

Table Information